TY - JOUR
T1 - Brain cancer propagating cells
T2 - biology, genetics and targeted therapies
AU - Hadjipanayis, Costas G.
AU - Van Meir, Erwin G.
N1 - Funding Information:
Our work is supported in part by grants from the NIH (CA86335, CA116804 to EGVM, NS053454 to CGH), American Brain Tumor Association (to CGH), Goldhirsh Foundation (to EGVM), Southeastern Brain Tumor Foundation (to CGH and EGVM), the Brain Tumor Funders Collaborative (to EGVM) and the Georgia Cancer Coalition, Distinguished Cancer Clinicians and Scientists Program (to CGH).
PY - 2009/11
Y1 - 2009/11
N2 - Cancer propagating cells (CPCs) within primary central nervous system (CNS) tumors (glioblastoma multiforme (GBM), medulloblastoma (MB) and ependymoma) might be integral to tumor development and perpetuation. These cells, also known as brain cancer propagating cells (BCPCs), have the ability to self-renew and proliferate. BCPCs can initiate new tumors in mice with high efficiency and these exhibit many features that are characteristic of patient's brain tumors. Accumulating evidence suggests that BCPCs might originate from the transformation of neural stem cells (NSCs) and their progenitors. Furthermore, recent studies have shown that NSC surface markers also define BCPCs. Ultimately, treatments that include specific targeting of BCPCs might potentially be more effective at treating the entire tumor mass, translating to improved patient survival and quality of life.
AB - Cancer propagating cells (CPCs) within primary central nervous system (CNS) tumors (glioblastoma multiforme (GBM), medulloblastoma (MB) and ependymoma) might be integral to tumor development and perpetuation. These cells, also known as brain cancer propagating cells (BCPCs), have the ability to self-renew and proliferate. BCPCs can initiate new tumors in mice with high efficiency and these exhibit many features that are characteristic of patient's brain tumors. Accumulating evidence suggests that BCPCs might originate from the transformation of neural stem cells (NSCs) and their progenitors. Furthermore, recent studies have shown that NSC surface markers also define BCPCs. Ultimately, treatments that include specific targeting of BCPCs might potentially be more effective at treating the entire tumor mass, translating to improved patient survival and quality of life.
UR - https://www.scopus.com/pages/publications/70449099233
U2 - 10.1016/j.molmed.2009.09.003
DO - 10.1016/j.molmed.2009.09.003
M3 - Review article
C2 - 19889578
AN - SCOPUS:70449099233
SN - 1471-4914
VL - 15
SP - 519
EP - 530
JO - Trends in Molecular Medicine
JF - Trends in Molecular Medicine
IS - 11
ER -